2023
DOI: 10.4274/qrheumatol.galenos.2023.76476
|View full text |Cite
|
Sign up to set email alerts
|

Tofacitinib: Current Considerations in the Management of Immune Inflammatory Disorders

Abstract: INVITED REVIEWTofacitinib, the first member of targeted-synthetic disease-modifying antirheumatic drugs, is an oral inhibitor of Janus kinases (JAKs), preferentially JAK-1 and 3. It is an analog of adenosine triphosphate and inhibits several pro-inflammatory cytokines and pathways. Tofacitinib is rapidly absorbed and eliminated mainly via the liver. The efficacy of tofacitinib has been studied extensively in patients with RA patients with different clinical scenarios. Now, tofacitinib is approved in several co… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 38 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?